Drug Landscape ›
Vicodin ›
Regulatory · United States
Marketing authorisations
FDA — authorised 25 May 1984
Application: ANDA085667
Marketing authorisation holder: ABBOTT
Local brand name: VICODIN
Indication: TABLET — ORAL
Status: approved
Read official source →
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 34,183
Most-reported reactions
Drug Dependence — 6,844 reports (20.02%) Pain — 6,124 reports (17.92%) Emotional Distress — 3,367 reports (9.85%) Nausea — 3,036 reports (8.88%) Overdose — 2,897 reports (8.47%) Drug Withdrawal Syndrome — 2,551 reports (7.46%) Anxiety — 2,444 reports (7.15%) Fatigue — 2,420 reports (7.08%) Drug Ineffective — 2,383 reports (6.97%) Depression — 2,117 reports (6.19%)
Source database →
Vicodin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Vicodin approved in United States?
Yes. FDA authorised it on 25 May 1984; FDA has authorised it.
Who is the marketing authorisation holder for Vicodin in United States?
ABBOTT holds the US marketing authorisation.